Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Nanfang Hospital, Southern Medical University20 enrolled

Overview

Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age≥18 years at the time of signing informed consent; * Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8); * Previously received SBRT and concurrent PD-1 blockade treatment； * Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria. Exclusion Criteria: * Patients who cannot be adequately followed up; * Has a known additional malignancy that is progressing or requires active treatment.

Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts